Hua Medicine’s Second-Generation GKA HM-002-1005 Completes Phase Ia Study in the US
China-based Hua Medicine (HKG: 2552) has announced the successful completion of a Phase Ia study...
Shanghai MicuRx’s MRX-4/Contezolid Meets Primary Endpoint in Phase III cSSTI Study
Shanghai MicuRx Pharmaceutical Co., Ltd. (SHA: 688373) has announced that its Phase III study for...
CBC Group and Mubadala Acquire UCB’s Neurology and Allergy Business in China for $680 Million
Singapore-based healthcare private equity firm CBC Group and Mubadala Investment Company, a global investment company...
Simcere Zaiming Launches Phase III Trial for SERD Inhibitor SIM0270 in Breast Cancer
Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary, Simcere Zaiming, has announced the initiation of a...
Hua Medicine’s SENSITIZE Study Illuminates Dorzagliatin’s β-Cell Glucose Sensitivity Mechanism
China-based innovative drug developer Hua Medicine (HKG: 2552), with operations in the US and Hong...
Sunflower Pharmaceutical Group to Establish Joint Lab with Peking University for Bacterial Enzyme Research
China-based Sunflower Pharmaceutical Group Co., Ltd. (SHE: 002737) is poised to establish a joint laboratory...
Simcere Pharmaceutical’s Edaravone and Borneol Sublingual Tablets Approved for AIS Treatment in China
China-based Simcere Pharmaceutical Group Limited (HKG: 2096) has announced receiving marketing approval from the National...
Shanghai Pharmaceuticals Concludes Phase II Study for I037 in Acute Ischemic Stroke
Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607, SHA: 601607) has announced the completion of data...
Affinity (Shanghai) Secures Over RMB 400 Million in Series B2 Financing to Advance Oncology Drugs
Affinity (Shanghai), the parent company of Shanghai Affinity Biopharmaceutical Co., Ltd., has reportedly raised upwards...
Abogen Biosciences and Ruijin Hospital Launch Ruijin Abogen Nucleic Acid Drug Research Institute
China-based nucleic acid drug developer Suzhou Abogen Biosciences and Ruijin Hospital, a comprehensive Class 3A...
Henlius Biotech Initiates US Commercial Supply of Hanquyou, Biosimilar to Herceptin
Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the initiation of commercial supply of its...
ImmuneOnco Biopharmaceuticals Receives NMPA Approval for Lupus Nephritis Phase II Study
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541), a China-based biopharmaceutical company, has announced receiving approval from...
Healthgen Biotechnology’s Plant-Made Albumin Breakthrough: A Milestone in Serum Therapy
On November 30th, Healthgen Biotechnology Corp. announced a significant research outcome at the 9th Pharmaceutical...
Shanghai Cell Therapy Group’s Second Attempt at HK IPO Receives Green Light from CICC and CCB International
Shanghai Cell Therapy Group Co., Ltd., a leading player in China’s cellular medical health sector,...
Nanjing Leads Biolabs Commences IPO Process with Focus on Innovative Therapies
Nanjing Leads Biolabs Co., Ltd., a clinical-stage biopharmaceutical company focused on developing innovative therapies for...
XellSmart Bio-Pharmaceutical Achieves Milestone with First Patient Enrollment in Global iPSC Clinical Study for ALS
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd., in collaboration with Shanghai East Hospital (Tongji University Affiliated East...
Cutia Therapeutic’s CU-20401 Shows Positive Results in Phase II Subcutaneous Fat Reduction Study
China-based dermatology specialist Cutia Therapeutic (HKG: 2487) has revealed a positive readout from its Phase...
OBiO Technology Partners with Hanxin Biotechnology to Advance LNP Delivery System
China-based gene therapy Contract Research Organization (CRO) OBiO Technology (Shanghai) Co., Ltd (SHA: 688238) has...
NMPA Approves Shenzhen Mindray’s Innovative Dual-Mode Ultrasound Diagnostic System
The National Medical Products Administration (NMPA) has granted approval to Shenzhen Mindray Bio-Medical Electronics Co.,...
NMPA Approves Hangzhou Ruidi Biotechnology’s Steep Pulse Therapy Equipment for Tumor Treatment
China’s National Medical Products Administration (NMPA) has granted approval to Hangzhou Ruidi Biotechnology Co., Ltd...